Millrace Asset Group, Inc. Axogen, Inc. Transaction History

Millrace Asset Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$8.5 - $10.38 $882,716 - $1.08 Million	103,849 Added 55.22%	291,921 $2.67 Million
Q1 2023 May 11, 2023	BUY	$7.53 - $10.95 $1.42 Million - $2.06 Million	188,072 New	188,072 $1.78 Million
Q2 2019 Aug 13, 2019	SELL	$18.5 - $25.47 $1.94 Million - $2.67 Million	-105,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$14.62 - $22.13 $467,840 - $708,160	32,000 Added 43.84%	105,000 $2.21 Million
Q4 2018 Feb 13, 2019	BUY	$17.09 - $38.25 $1.03 Million - $2.3 Million	60,000 Added 461.54%	73,000 $1.49 Million
Q3 2018 Nov 13, 2018	SELL	$34.05 - $55.9 $226,160 - $371,287	-6,642 Reduced 33.82%	13,000 $479,000
Q2 2018 Aug 14, 2018	SELL	$36.15 - $52.5 $735,941 - $1.07 Million	-20,358 Reduced 50.9%	19,642 $987,000
Q1 2018 May 15, 2018	SELL	$24.4 - $40.25 $732,000 - $1.21 Million	-30,000 Reduced 42.86%	40,000 $1.46 Million
Q4 2017 Feb 13, 2018	SELL	$18.5 - $28.6 $925,000 - $1.43 Million	-50,000 Reduced 41.67%	70,000 $1.98 Million
Q3 2017 Nov 13, 2017	SELL	$14.65 - $19.35 $219,750 - $290,250	-15,000 Reduced 11.11%	120,000 $2.32 Million
Q2 2017 Aug 11, 2017	BUY	N/A	135,000	135,000 $2.26 Million

176

36.6M

230K

400

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $749M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

Get notified when there are updates to the investment portfolio of Millrace Asset Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Millrace Asset Group, Inc. with notifications on news.